_____________________
EBMT_EHA_CAR-T_CellHandbook-V2_2022.pdf
_____________________
Practical aspects of building a new immunotherapy
program: the future of cell therapy (2020)
_____________________
Haematology Nurses and
Healthcare Professionals (HNHCP) – CAR (Chimeric Antigen Receptor) T-cell
therapy: a resource for healthcare professionals (2022)
_____________________
Advanced Practice Nursing and CAR-T Cell Therapy: Opportunities,
Challenges and Future Directions (2024)
_____________________
Chimeric Antigen Receptor T CellTherapy Management and Safety:A Practical Tool From aMultidisciplinary Team Perspective (2021)
_____________________
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines
from the American Society for Transplantation and Cellular Therapy
_____________________
https://www.tecartus.com/_____________________Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) (2021)
__________________________
Leukapheresis guidance and best practices for optimal chimeric antigen
receptor T-cell manufacturing (2022)
__________________________
Leukapheresis for CAR-T cell production and therapy (2023)
__________________________
Lymphodepletion– an
essential but undervalued part
of the chimeric antigen
receptor T-cell therapy cycle (2023)
__________________________
Role of bridging therapy during chimeric antigen receptor
T cell therapy (2021)
__________________________
_____________________________________
How I treat adverse effects of CAR- T
cell therapy (2020)
_____________________________________
_____________________________________
Practical aspects of chimeric
antigen receptor T-cell
administration: From
commercial to point-of-care
manufacturing (2022)
_____________________________________
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy (2020)
_____________________________________
How I treat refractory CRS and ICANS after CAR
T-cell therapy (2023)
________________________________________
How I treat unique and difficult-to-manage cases of
CAR T-cell therapy–associated neurotoxicity (2023)
_____________________________________
Evaluation and management of chimeric antigen
receptor (CAR) T-cell-associated neurotoxicity (2020)
_____________________________________
Immune Effector Cell-Associated Hemophagocytic
Lymphohistiocytosis-Like Syndrome (2023)
_____________________________________
CAR T-cell therapy and critical care (2021)
_____________________________________
Critical Care Management of Chimeric Antigen Receptor
T- Cell Therapy Recipients (2022)
_____________________________________
Toxicities, intensive care management,
and outcome of chimeric antigen receptor T
cells in adults: an update (2024)
_____________________________________
CARDIAC Toxicity
Cardiotoxicity from chimeric antigen
receptor-T cell therapy for advanced
malignancies (2022)
_____________________________________
How I approach optimization of patients at risk of
cardiac and pulmonary complications after CAR
T-cell therapy (2023)
_____________________________________
Immune effector cell–associated hematotoxicity:
EHA/EBMT consensus grading and best practice
recommendations (2023)
_____________________________________
CAR-HEMATOTOX: a model for CAR T-cell–related
hematologic toxicity in relapsed/refractory large
B-cell lymphoma (2021)
_____________________________________
The CAR‑HEMATOTOX score as a prognostic
model of toxicity and response in patients
receiving BCMA‑directed CAR‑T for relapsed/
refractory multiple myeloma (2023)
_____________________________________
The CAR- HEMATOTOX risk- stratifies
patients for severe infections and
disease progression after CD19 CAR- T
in R/R LBCL (2022)
_____________________________________
_____________________________________
Immune effector cell-associated haematotoxicity after
CAR T-cell therapy: from mechanism to management (2024)
________________________________________
How I treat cytopenias after CAR T-cell therapy (2023)
____________________________________
Infectious complications, immune reconstitution, and infection
prophylaxis after CD19 chimeric antigen receptor T-cell therapy (2022)
____________________________________
Best Practice Considerations by The American Society of
Transplant and Cellular Therapy: Infection Prevention and
Management After Chimeric Antigen Receptor T Cell Therapy
for Hematological Malignancies (2024)
____________________________________
MANAGING INFECTION COMPLICATIONS IN THE SETTING OF
CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T) THERAPY
(2024)
____________________________________
How I prevent infections in patients receiving
CD19-targeted chimeric antigen receptor T cells for
B-cell malignancies. (2020)
____________________________________
Chimeric antigen receptor T-cell therapy: An emergency medicine
focused review (2021)
____________________________________
Five-Year Follow-Up of Standard-of-Care Axicabtagene
Ciloleucel for Large B-Cell Lymphoma: Results From the US
Lymphoma CAR T Consortium (2024)
____________________________________
Therapeutic options for large B-cell lymphoma relapsing after
CD19-directed CAR T-cell therapy (2023)
____________________________________
Cellular Therapy & Hematology Resources 